Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan;30(1):28-38.
doi: 10.1016/j.jsps.2021.12.002. Epub 2021 Dec 20.

Localizing pharmaceuticals manufacturing and its impact on drug security in Saudi Arabia

Essam A Tawfik  1 , Abdulkader F Tawfik  2 , Areej M Alajmi  1 , Moutaz Y Badr  3 , Ahmed Al-Jedai  4   5 , Nada H Almozain  6 , Haitham A Bukhary  3 , Abdulrahman A Halwani  7 , Saeed A Al Awadh  8 , Aws Alshamsan  9 , Salim Babhair  10 , Abdulaziz M Almalik  1
Affiliations
Review

Localizing pharmaceuticals manufacturing and its impact on drug security in Saudi Arabia

Essam A Tawfik et al. Saudi Pharm J. 2022 Jan.

Abstract

Local production of pharmaceuticals plays a vital role in maintaining resilience of national healthcare systems, especially when it comes to facilitating access to needed medicines and decreasing exposure to imports and international supply chains. Pharma is a research-intensive industry and the systemic lack of governance and support to R&D activities in this sector, among other host of related issues such as unsupportive regulatory regimes and human resources capacity limitations, is one of the major impediments to the diversifying of locally produced pharmaceuticals portfolio. In this review, an overview of the current pharmaceutical production system in Saudi Arabia, its major challenges, and proposed remedies to address them will be highlighted.

Keywords: Pharmaceutical innovation; Pharmaceutical market; Pharmaceutical production system; Pharmaceuticals manufacturing in Saudi Arabia; Research and development (R&D).

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

None
Graphical abstract
Fig. 1
Fig. 1
Challenges facing the pharmaceutical industry in Saudi Arabia.
Fig. 2
Fig. 2
Proposed financial and non-financial initiatives to advance the RDI ecosystem in Saudi Arabia.
See this image and copyright information in PMC

References

    1. Al-Jazairi A.S., Al-Qadheeb N.S., Ajlan A. Pharmacoeconomic analysis in Saudi Arabia: an overdue agenda item for action. Ann. Saudi Med. 2011;31(4):335–341. - PMC - PubMed
    1. Alhawassi T.M., Abuelizz H.A., Almetwazi M., Mahmoud M.A., Alghamdi A., Alruthia Y.S., BinDhim N., Alburikan K.A., Asiri Y.A., Pitts P.J. Advancing pharmaceuticals and patient safety in Saudi Arabia: a 2030 vision initiative. Saudi Pharmaceut J.: SPJ: Off. Publ. Saudi Pharmaceut. Soc. 2018;26(1):71–74. doi: 10.1016/j.jsps.2017.10.011. - DOI - PMC - PubMed
    1. Ali S., Alghamdi M.A., Alzhrani J.A., De Vol E.B. Magnitude and characteristics of clinical trials in the Kingdom of Saudi Arabia: a cross-sectional analysis. Contemp. Clin. Trials Commun. 2017;7:126–129. - PMC - PubMed
    1. Aljadhey H., Mahmoud M.A., Alshammari T.M., Al-Dhaeefi M., Louet H.L., Perez-Gutthann S., Pitts P.J. A qualitative exploration of the major challenges facing pharmacovigilance in Saudi Arabia. SMJ. 2015;36(9):1097–1102. - PMC - PubMed
    1. AlKhamees O.A., AlNemer K.A., Bin Maneea M.W., AlSugair F.A., AlEnizi B.H., Alharf A.A. Top 10 most used drugs in the Kingdom of Saudi Arabia 2010–2015. Saudi Pharmaceut. J. 2018;26(2):211–216. - PMC - PubMed

LinkOut - more resources